Torl Bio

TORL BioTherapeutics is a clinical-stage biopharmaceutical business.

Health and bio

TIMELINE · MONEY RAISED

Torl Bio | 1309 days on the record

Raised $412M in 3 sourced rounds

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

1. October 7, 2025
   Series B+ · $96M
   Source: fundraisingfox.com
2. April 10, 2024
   Series B+ · $158M
   DDeep Track Capital (lead), GGianna Hoffman-Luca, GGoldman Sachs, MMoore Strategic Ventures, PPerceptive Advisors, RRA Capital Management, UUC Investments, UUCOP, VVertex Ventures HC, XXontogeny
   Source: prnewswire.com
3. April 13, 2023
   Series B+ · $158M
   GGoldman Sachs Asset Management (lead), BBristol-Myers Squibb, CCowen Healthcare Investments, DDeep Track Capital, MMoore Strategic Ventures, OOCV, PPerceptive Advisors, UUC Investments, VVertex Ventures HC, VVest Coast Capital
   Source: fundraisingfox.com
4. February 10, 2020
   Website created

Founders and team

• DL
  David Licata Founder

  LinkedIn
• DS
  Dennis Slamon Founder

  LinkedIn
• AM
  Aran Maree Chief Executive Officer
• CL
  Christine Loggins Chief Operating Officer
• SR
  Steve Ritland Chief Scientific Officer
• VR
  Vince Ruiz General Counsel

Investors

• BBlue Owl Capital
• BBristol-Myers Squibb
• CCowen Healthcare Investments
• DDeep Track Capitallead investor
• GGianna Hoffman-Luca
• GGoldman Sachs
• GGoldman Sachs Asset Managementlead investor
• MMoore Strategic Ventures
• OOCV
• PPerceptive Advisors
• RRA Capital Management
• UUC Investments
• UUCOP
• VVertex Ventures HC
• VVest Coast Capital
• XXontogeny

Companies like Torl Bio

• TTiltbio$25M Series B+ · May 2025
• LLifeMine Therapeutics$75M Series B+ · Aug 2026
• CCellCentric$220M Series B+ · May 2026
• IIDRx$120M Series B+ · Aug 2024
• 335PharmaSeries B+ · Nov 2024
• RR1 Therapeutics$80.5M Series A · Sep 2026

Other companies backed by Deep Track Capital

• EEstuary Biotherapeutics$103M Series A · Oct 2026
• DDraig Therapeutics$65M Series B+ · Jul 2026
• OOblenio Bio$62M Series B+ · Jun 2026
• TTubulis$360M Series B+ · Oct 2025
• AArbor Biotechnologies$74M Series B+ · Mar 2025
• MMariana Oncology$175M Series B+ · Sep 2023

Deep Track Capital portfolio →